• SENSEX
    NIFTY 50
Market

This pharma stock rose 21% after CLSA's rating change; Find out more

Updated : November 18, 2019 03:47 PM IST

Global brokerage CLSA upgraded Glenmark Pharma to 'buy' from 'sell' and raised its target price to Rs 410 per share from Rs 350 earlier.
The stock gained as much as 8.7 percent to Rs 327.60 per share on BSE.
Glenmark Pharma has advanced 16 percent in just 2 days post Q2 results.
This pharma stock rose 21% after CLSA's rating change; Find out more

You May Also Like

Live TV
Advertisement